Train drivers vote to increase strike motion
Pfizer has dropped its plans for a twice-daily weight-loss capsule after trials confirmed it prompted important unwanted side effects.
The halt of its growth is a blow to the drugmaker’s hopes of capitalising on the clamour for weight problems remedies in gentle of the success of Wegovy, developed by Danish rival Novo Nordisk.
Pfizer shares fell 5.9pc after markets opened on Wall Street after greater than half of the members in its scientific trial for the brand new drug dropped out over its unwanted side effects.
The firm had mentioned final 12 months that its oral weight problems capsules may generate greater than $10bn (£7.9bn) in future revenues.
It ended the trial of danuglipron after members within the trial reported gastrointestinal unwanted side effects, with many reporting nausea, vomiting and diarrhea.
Read the newest updates beneath.